146 related articles for article (PubMed ID: 10082503)
1. Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans.
Azizi M; Ezan E; Reny JL; Wdzieczak-Bakala J; Gerineau V; Ménard J
Hypertension; 1999 Mar; 33(3):879-86. PubMed ID: 10082503
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin I-converting enzyme and metabolism of the haematological peptide N-acetyl-seryl-aspartyl-lysyl-proline.
Azizi M; Junot C; Ezan E; Ménard J
Clin Exp Pharmacol Physiol; 2001 Dec; 28(12):1066-9. PubMed ID: 11903317
[TBL] [Abstract][Full Text] [Related]
3. Substrate dependence of angiotensin I-converting enzyme inhibition: captopril displays a partial selectivity for inhibition of N-acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I.
Michaud A; Williams TA; Chauvet MT; Corvol P
Mol Pharmacol; 1997 Jun; 51(6):1070-6. PubMed ID: 9187274
[TBL] [Abstract][Full Text] [Related]
4. Effect of angiotensin-converting enzyme inhibition on plasma, urine, and tissue concentrations of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro in rats.
Junot C; Nicolet L; Ezan E; Gonzales MF; Menard J; Azizi M
J Pharmacol Exp Ther; 1999 Dec; 291(3):982-7. PubMed ID: 10565814
[TBL] [Abstract][Full Text] [Related]
5. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition.
Azizi M; Ezan E; Nicolet L; Grognet JM; Ménard J
Hypertension; 1997 Nov; 30(5):1015-9. PubMed ID: 9369248
[TBL] [Abstract][Full Text] [Related]
6. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline.
Azizi M; Rousseau A; Ezan E; Guyene TT; Michelet S; Grognet JM; Lenfant M; Corvol P; Ménard J
J Clin Invest; 1996 Feb; 97(3):839-44. PubMed ID: 8609242
[TBL] [Abstract][Full Text] [Related]
7. In vivo assessment of captopril selectivity of angiotensin I-converting enzyme inhibition: differential inhibition of acetyl-ser-asp-lys-pro and angiotensin I hydrolysis.
Junot C; Menard J; Gonzales MF; Michaud A; Corvol P; Ezan E
J Pharmacol Exp Ther; 1999 Jun; 289(3):1257-61. PubMed ID: 10336514
[TBL] [Abstract][Full Text] [Related]
8. Nonadherence with angiotensin-converting enzyme inhibitor therapy: a comparison of different ways of measuring it in patients with chronic heart failure.
Struthers AD; MacFadyen R; Fraser C; Robson J; Morton JJ; Junot C; Ezan E
J Am Coll Cardiol; 1999 Dec; 34(7):2072-7. PubMed ID: 10588226
[TBL] [Abstract][Full Text] [Related]
9. N-acetyl-seryl-aspartyl-lysyl-proline mediates the anti-fibrotic properties of captopril in unilateral ureteric obstructed BALB/C mice.
Chan GCW; Wu HJ; Chan KW; Yiu WH; Zou A; Huang XR; Lan HY; Lai KN; Tang SCW
Nephrology (Carlton); 2018 Apr; 23(4):297-307. PubMed ID: 28075040
[TBL] [Abstract][Full Text] [Related]
10. Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements.
Le Meur Y; Lorgeot V; Comte L; Szelag JC; Aldigier JC; Leroux-Robert C; Praloran V
Am J Kidney Dis; 2001 Sep; 38(3):510-7. PubMed ID: 11532682
[TBL] [Abstract][Full Text] [Related]
11. Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension.
Peng H; Carretero OA; Liao TD; Peterson EL; Rhaleb NE
Hypertension; 2007 Mar; 49(3):695-703. PubMed ID: 17283252
[TBL] [Abstract][Full Text] [Related]
12. Metabolic reprogramming by N-acetyl-seryl-aspartyl-lysyl-proline protects against diabetic kidney disease.
Srivastava SP; Goodwin JE; Kanasaki K; Koya D
Br J Pharmacol; 2020 Aug; 177(16):3691-3711. PubMed ID: 32352559
[TBL] [Abstract][Full Text] [Related]
13. Myelopoiesis modulation by ACE hyperfunction in kinin B(1) receptor knockout mice: relationship with AcSDKP levels.
Oliveira CR; Paredes-Gamero EJ; Barbosa CM; Nascimento FD; Batista EC; Reis FC; Martins AH; Ferreira AT; Carmona AK; Pesquero JB; Tersariol IL; Araújo RC; Bincoletto C
Chem Biol Interact; 2010 Mar; 184(3):388-95. PubMed ID: 20096676
[TBL] [Abstract][Full Text] [Related]
14. Clinical Implications of Plasma N-acetyl-seryl-aspartyl-lysyl-proline Level in Stable Kidney Transplant Recipients.
Suzuki Y; Katagiri F; Sato F; Fujioka K; Sato Y; Fujioka T; Sato Y; Mimata H; Itoh H
Clin Lab; 2016 Jul; 62(7):1323-1328. PubMed ID: 28164637
[TBL] [Abstract][Full Text] [Related]
15. Significant decrease in plasma N-acetyl-seryl-aspartyl-lysyl-proline level in patients with end stage renal disease after kidney transplantation.
Suzuki Y; Katagiri F; Sato F; Fujioka K; Sato Y; Fujioka T; Sato Y; Mimata H; Itoh H
Biol Pharm Bull; 2014; 37(6):1075-9. PubMed ID: 24882420
[TBL] [Abstract][Full Text] [Related]
16. Sodium restriction on top of renin-angiotensin-aldosterone system blockade increases circulating levels of N-acetyl-seryl-aspartyl-lysyl-proline in chronic kidney disease patients.
Kwakernaak AJ; Waanders F; Slagman MC; Dokter MM; Laverman GD; de Boer RA; Navis G
J Hypertens; 2013 Dec; 31(12):2425-32. PubMed ID: 24029871
[TBL] [Abstract][Full Text] [Related]
17. Catabolism of the hemoregulatory peptide N-Acetyl-Ser-Asp-Lys-Pro: a new insight into the physiological role of the angiotensin-I-converting enzyme N-active site.
Rousseau-Plasse A; Lenfant M; Potier P
Bioorg Med Chem; 1996 Jul; 4(7):1113-9. PubMed ID: 8831983
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Angiotensin-Converting Enzyme Ameliorates Renal Fibrosis by Mitigating DPP-4 Level and Restoring Antifibrotic MicroRNAs.
Srivastava SP; Goodwin JE; Kanasaki K; Koya D
Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32085655
[TBL] [Abstract][Full Text] [Related]
19. The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme.
Rousseau A; Michaud A; Chauvet MT; Lenfant M; Corvol P
J Biol Chem; 1995 Feb; 270(8):3656-61. PubMed ID: 7876104
[TBL] [Abstract][Full Text] [Related]
20. Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen.
Nitta K; Shi S; Nagai T; Kanasaki M; Kitada M; Srivastava SP; Haneda M; Kanasaki K; Koya D
Biomed Res Int; 2016; 2016():9172157. PubMed ID: 27088094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
